Levothyroxine Sodium 100 mcg Tablets Recalled for Potency Deviations Nationwide
Mylan Institutional is recalling 2,835 cartons of Levothyroxine Sodium 100 mcg tablets nationwide due to potency deviations—some tablets may be underdosed while others may be overdosed.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving a critical thyroid hormone medication with potency deviations that could result in improper dosing. No illnesses have been reported, but this qualifies as a risk-of-harm product where injury has not yet been reported, per the severity rubric.
Plain-English summary
Mylan Institutional, Inc. is recalling 2,835 cartons of Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), distributed nationwide in the United States. The recall involves Lot #3115936 with an expiration date of 07/2025 (NDC 51079-442-20). The tablets are being recalled due to potency deviations—some tablets may be subpotent (containing insufficient active ingredient) while others may be superpotent (containing excessive active ingredient). Levothyroxine sodium is a thyroid hormone replacement medication used to treat hypothyroidism, and potency variations could result in patients receiving improper doses.
This recall affects healthcare facilities, pharmacies, and patients who received Levothyroxine Sodium from Lot #3115936 with expiration date 07/2025. Any individual or facility that may have received this product should verify their supply.
Patients should contact their healthcare provider if they have Levothyroxine Sodium tablets from this lot. Healthcare providers and pharmacies should discontinue distribution and quarantine affected inventory. The FDA classified this as a Class II recall. Additional information is available through the FDA's drug recall database.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Mylan Institutional, Inc.
- Hazard
- potency-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 3115936
- Exp. Date 07/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium tablets recalled for impurity specification failure
FDA (Drugs) · 2025-01-08
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Tablets
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27